Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Venetian: A Phase 2b/3 Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) and Optimize Initiation of Venetoclax (Ven) in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)

William G. Wierda, Matthew S. Davids, Jeff P. Sharman, Nilanjan Ghosh, Yang Feng, Mary Jean Fusco, Jacqueline Hilger-Rolfe, Chen Qian, Wendy J. Sinai, Sophie Wimberley, John F. Seymour

Blood (2024) 144 (Supplement 1): 6784.

https://doi.org/10.1182/blood-2024-207716

Published: 2024

Journal Articles

Gene Correction of DNMT3A:R882H in Primary Human AML Demonstrates That This Mutation Is Not Required for Disease Maintenance, but Is Associated with Increased Leukemia Stem Cell Frequency

Thomas Koehnke, Daiki Karigane, Eleanor Hilgart, Kensuke Kayamori, Amy C Fan, Cailin T Collins, Fabian P Suchy, Athreya S Rangavajhula, Yang Feng, Yusuke Nakauchi, Eduardo Martinez-Montes, Michael Koldobskiy, Andy Feinberg, Ravindra Majeti

Blood (2023) 142 (Supplement 1): 579.

https://doi.org/10.1182/blood-2023-186440

Published: 2023

Journal Articles

Dnmt3a Mutations in the Hematopoietic System Promote Colitis-Associated Colon Cancer: A Model of Clonal Hematopoiesis in Solid Tumors

Yang Feng, Rachel Newsome, Troy Robinson, Robert L. Bowman, Ashley Zuniga, Kendra Hall, Cassandra Bernsten, Daniil Shabashvili, Kathryn Krajcik, Chamara Gunaratne, Zachary Zaroogian, Kartika Venugopal, Heidi Casellas Roman, Ross L. Levine, Alberto Riva, Daniel Kopinke, Christian Jobin, Dorina Avram, Olga A Guryanova

Blood (2021) 138 (Supplement 1): 2161.

https://doi.org/10.1182/blood-2021-149740

Published: 2021

Journal Articles

DNMT3A with Leukemia-Associated R882 Mutations Promotes Fitness Advantage through Functional Heterogeneity within HSCs

Zachary Zaroogian, Chamara Gunaratne, Daniil Shabashvili, Cassandra Berntsen, Yang Feng, Kartika Venugopal, Santhi Pondugula, Olga A Guryanova

Blood (2021) 138 (Supplement 1): 2151.

https://doi.org/10.1182/blood-2021-151007

Published: 2021

Journal Articles

DNMT3A with Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks

Kartika Venugopal, MS, Daniil E Shabashvili, PhD, Jianping Li, MD, Luisa M Posada, Richard Lynn Bennett, PhD, Yang Feng, MS, Daphne Dupere Richer, PhD, Alberto Riva, PhD, Santhi Pondugula, PhD, Jonathan E. Bird, PhD, Jonathan D. Licht, MD, Olga A Guryanova, MD PhD

Blood (2019) 134 (Supplement_1): 535.

https://doi.org/10.1182/blood-2019-128213

Published: 2019

Journal Articles

Cells with DNMT3A Mutations Are More Sensitive to Cytarabine-Induced DNA Damage

Kartika Venugopal, MS, Jianping Li, MD, Daniil E Shabashvili, PhD, Luisa M Posada, Yang Feng, MS, Daphne Dupere-Richer, PhD, Aditya Bele, PhD, Jonathan D. Licht, MD, Olga A Guryanova, MD PhD

Blood (2018) 132 (Supplement 1): 2643.

https://doi.org/10.1182/blood-2018-99-118708

Published: 2018

Journal Articles

Targeting of folate receptor β on acute myeloid leukemia blasts with chimeric antigen receptor–expressing T cells

Rachel C. Lynn, Mathilde Poussin, Anna Kalota, Yang Feng, Philip S. Low, Dimiter S. Dimitrov, Daniel J. Powell, Jr

Blood (2015) 125 (22): 3466–3476.

https://doi.org/10.1182/blood-2014-11-612721

Published: 2015

Includes: Supplemental data

Journal Articles

Ofatumumab As Initial Therapy For Indolent B Cell Lymphomas: A Phase II Trial

Jeffrey A. Barnes, MD, PhD, Yang Feng, PhD, Ephraim P Hochberg, MD, Tak Takvorian, MD, James Weitzman, MD, David C. Fisher, MD, Eric D. Jacobsen, MD, Robin Joyce, MD, Donna S. Neuberg, ScD, Jeremy S. Abramson, MD

Blood (2013) 122 (21): 3062.

https://doi.org/10.1182/blood.V122.21.3062.3062

Published: 2013

Journal Articles

Double Hit Lymphomas: Evaluation of Prognostic Factors and Impact of Therapy

Jeremy S. Abramson, MD, Jeffrey A. Barnes, MD, PhD, Yang Feng, PhD, Tak Takvorian, MD, Donna S. Neuberg, ScD, Ephraim P. Hochberg, MD, Aliyah R. Sohani, MD

Blood (2012) 120 (21): 1619.

https://doi.org/10.1182/blood.V120.21.1619.1619

Published: 2012

Journal Articles

Association of Baseline Body Mass Index (BMI) with Overall Survival Among Patients Over Age 60 with Acute Myeloid Leukemia (AML)

Andrew M. Brunner, MD, Yang Feng, PhD, Benjamin J. Drapkin, MD, Hossein Sadrzadeh, MD, Karen K. Ballen, MD, Eyal C. Attar, MD, Philip C. Amrein, MD, Steven L. McAfee, MD, Donna S. Neuberg, ScD, Amir T Fathi, MD

Blood (2012) 120 (21): 1484.

https://doi.org/10.1182/blood.V120.21.1484.1484

Published: 2012

Journal Articles

Secondary Central Nervous System Lymphoma: A Single Center Experience

Gregory M. Cote, MD, PhD, Yang Feng, PhD, Aliyah R. Sohani, MD, Zachary J. Roberts, MD, PhD, Anna Colpo, MD, Fred H Hochberg, MD, Yi-Bin A. Chen, MD, James S. Michaelson, PhD, Donna Neuberg, ScD, Jeremy S. Abramson, MD, Ephraim P. Hochberg, MD

Blood (2011) 118 (21): 5181.

https://doi.org/10.1182/blood.V118.21.5181.5181

Published: 2011

Journal Articles

Everolimus in Combination with Rituximab Induces Complete Responses in Heavily Pretreated Diffuse Large B-Cell Lymphoma

Jeffrey A. Barnes, MD, PhD, Eric Jacobsen, MD, Yang Feng, PhD, Arnold S. Freedman, MD, Ephraim P. Hochberg, MD, Ann S. LaCasce, MD, Philippe Armand, MD, PhD, Robin Joyce, MD, Donna Neuberg, ScD, David C. Fisher, MD, Jeremy S. Abramson, MD

Blood (2011) 118 (21): 1635.

https://doi.org/10.1182/blood.V118.21.1635.1635

Published: 2011

Journal Articles

High Rate of Initial Treatment Failure in Patients with Primary Mediastinal B-Cell Lymphoma Treated with R-CHOP

Jeremy S. Abramson, MD, Matthew D Hellmann, MD, Yang Feng, PhD, Jeffrey A. Barnes, MD, PhD, Tak Takvorian, MD, Christiana E. Toomey, Michael Sheppard, James S. Michaelson, PhD, Donna Neuberg, ScD, Ephraim P. Hochberg, MD

Blood (2011) 118 (21): 1601.

https://doi.org/10.1182/blood.V118.21.1601.1601

Published: 2011

Journal Articles

Risk Factors Associated with the Development of Pneumonitis After High-Dose Chemotherapy with Cyclophosphamide, BCNU, and Etoposide (CBV) Followed by Autologous Stem Cell Transplant

Andrew A. Lane, MD, PhD, Philippe Armand, MD, PhD, Yang Feng, Donna Neuberg, ScD, Jeremy S. Abramson, MD, Jennifer R. Brown, MD, PhD, David C. Fisher, MD, Ann S. LaCasce, MD, MSc, Eric D. Jacobsen, MD, Steven L. McAfee, MD, Thomas R. Spitzer, MD, Arnold S. Freedman, MD, Yi-Bin Chen, MD

Blood (2010) 116 (21): 903.

https://doi.org/10.1182/blood.V116.21.903.903

Published: 2010

Journal Articles

A Phase I Dose-Escalation Trial of Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma

Jeremy S Abramson, MD, Tak Takvorian, MD, Eric D Jacobsen, MD, Jennifer R Brown, MD, PhD, Jeffrey A. Barnes, MD, PhD, Yang Feng, Donna Neuberg, ScD, Ephraim P. Hochberg, MD

Blood (2010) 116 (21): 1775.

https://doi.org/10.1182/blood.V116.21.1775.1775

Published: 2010

Journal Articles

Rituximab Added to CODOX-M/IVAC has No Clear Benefit Compared to CODOX-M/IVAC alone in Adult Patients with Burkitt Lymphoma.

Barnes A. Barnes, MD, PhD, Ann S. LaCasce, MD, Yang Feng, Christiana Toomey, Donna Neuberg, ScD, Ephraim P. Hochberg, MD, Jeremy S. Abramson, MD

Blood (2009) 114 (22): 1667.

https://doi.org/10.1182/blood.V114.22.1667.1667

Published: 2009

Journal Articles

Impact of the Addition of Rituximab to Initial CHOP Chemotherapy Compared with CHOP Alone in Patients with Relapsed Diffuse Large B-Cell Lymphoma Who Underwent Autologous Stem Cell Transplantation.

Yi-Bin Chen, MD, Ephraim P. Hochberg, MD, Yang Feng, MS, MPH, Gabriela Motyckova, MD, Donna Neuberg, Sc.D., Thomas R. Spitzer, MD, David C. Fisher, MD, Ann S. LaCasce, MD

Blood (2007) 110 (11): 5124.

https://doi.org/10.1182/blood.V110.11.5124.5124

Published: 2007

Journal Articles

A Phase 2 Study of Fludarabine and Rituximab for the Treatment of Marginal Zone Lymphomas.

Jennifer R. Brown, MD, PhD, Jonathan Friedberg, MD, Yang Feng, MS, Kimberly Phillips, BA, Jennifer C. Clark, MA, Paola dal Cin, PhD, Robin Joyce, MD, David C. Fisher, MD, Richard I. Fisher, MD, Ronald W. Takvorian, MD, Jane Liesveld, MD, Diana Marquis, BS, Donna Neuberg, ScD, Arnold S. Freedman, MD

Blood (2007) 110 (11): 1358.

https://doi.org/10.1182/blood.V110.11.1358.1358

Published: 2007

Journal Articles

Long-Term Follow-Up of Autologous Bone Marrow Transplantation for Follicular Lymphoma in First Remission: Bone Marrow Involvement at Harvest and PCR Detectable Disease after Ex Vivo Purging Predict Relapse.

Jennifer R. Brown, MD, PhD, John G. Gribben, MD DPhil, Yang Feng, MS MPH, Donna Neuberg, DSc, Peter Mauch, MD, Lee M. Nadler, MD, Arnold S. Freedman, MD

Blood (2006) 108 (11): 3041.

https://doi.org/10.1182/blood.V108.11.3041.3041

Published: 2006

Journal Articles

Human interleukin-9: genomic sequence, chromosomal location, and sequences essential for its expression in human T-cell leukemia virus (HTLV)-I-transformed human T cells

K Kelleher, K Bean, SC Clark, WY Leung, TL Yang-Feng, JW Chen, PF Lin, W Luo, YC Yang

Blood (1991) 77 (7): 1436–1441.

https://doi.org/10.1182/blood.V77.7.1436.1436

Published: 1991

NARROW

Venetian: A Phase 2b/3 Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) and Optimize Initiation of Venetoclax (Ven) in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Gene Correction of DNMT3A:R882H in Primary Human AML Demonstrates That This Mutation Is Not Required for Disease Maintenance, but Is Associated with Increased Leukemia Stem Cell Frequency

Dnmt3a Mutations in the Hematopoietic System Promote Colitis-Associated Colon Cancer: A Model of Clonal Hematopoiesis in Solid Tumors

DNMT3A with Leukemia-Associated R882 Mutations Promotes Fitness Advantage through Functional Heterogeneity within HSCs

DNMT3A with Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks

Cells with DNMT3A Mutations Are More Sensitive to Cytarabine-Induced DNA Damage

Targeting of folate receptor β on acute myeloid leukemia blasts with chimeric antigen receptor–expressing T cells

Ofatumumab As Initial Therapy For Indolent B Cell Lymphomas: A Phase II Trial

Double Hit Lymphomas: Evaluation of Prognostic Factors and Impact of Therapy

Association of Baseline Body Mass Index (BMI) with Overall Survival Among Patients Over Age 60 with Acute Myeloid Leukemia (AML)

Secondary Central Nervous System Lymphoma: A Single Center Experience

Everolimus in Combination with Rituximab Induces Complete Responses in Heavily Pretreated Diffuse Large B-Cell Lymphoma

High Rate of Initial Treatment Failure in Patients with Primary Mediastinal B-Cell Lymphoma Treated with R-CHOP

Risk Factors Associated with the Development of Pneumonitis After High-Dose Chemotherapy with Cyclophosphamide, BCNU, and Etoposide (CBV) Followed by Autologous Stem Cell Transplant

A Phase I Dose-Escalation Trial of Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma

Rituximab Added to CODOX-M/IVAC has No Clear Benefit Compared to CODOX-M/IVAC alone in Adult Patients with Burkitt Lymphoma.

Impact of the Addition of Rituximab to Initial CHOP Chemotherapy Compared with CHOP Alone in Patients with Relapsed Diffuse Large B-Cell Lymphoma Who Underwent Autologous Stem Cell Transplantation.

A Phase 2 Study of Fludarabine and Rituximab for the Treatment of Marginal Zone Lymphomas.

Long-Term Follow-Up of Autologous Bone Marrow Transplantation for Follicular Lymphoma in First Remission: Bone Marrow Involvement at Harvest and PCR Detectable Disease after Ex Vivo Purging Predict Relapse.

Human interleukin-9: genomic sequence, chromosomal location, and sequences essential for its expression in human T-cell leukemia virus (HTLV)-I-transformed human T cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only